Derek Raghavan

28.9k citations
296 papers · 19.2k · 9 hit papers · h-index 50

Impact in

  • Surgery top 0.05%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies
  • Oncology top 0.2%
    • Cancer Cells and Metastasis

Papers in

    • Bladder and Urothelial Cancer Treatments 83
    • Testicular diseases and treatments 38
    • Urinary and Genital Oncology Studies 33
    • Prostate Cancer Treatment and Research 43
    • Lung Cancer Treatments and Mutations 16

Derek Raghavan

288 papers receiving 18.7k citations

Derek Raghavan's Hit Papers

American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology 2012 · 464 citations
4640+11+22Years since publication50010001.5k2.0k2.5k

Peers

Derek Raghavan
Comparison fields: 5 of 145
  • Surgery 8.3k
  • Oncology 4.8k
  • Pulmonary and Respiratory Medicine 5.4k
  • Urology 993
  • Cancer Research 2.3k
Replace Yves Fradet with:
Yves Fradet Canada
E. David Crawford United States
Joaquim Bellmunt United States
Harm van Tinteren Netherlands
James E. Montie United States
Paul F. Schellhammer United States
Colin P. Dinney United States
Guru Sonpavde United States
Dean F. Bajorin United States
Daniel P. Petrylak United States
Derek Raghavan relative to Yves Fradet Canada Yves Fradet's profile →
Citations per field
00.5×1.5×
Yves Fradet · 1×
Citations per year

Countries citing papers authored by Derek Raghavan

Since Specialization
Citations

This map shows the geographic impact of Derek Raghavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Raghavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Raghavan more than expected).

Fields of papers citing papers by Derek Raghavan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek Raghavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Raghavan. The network helps show where Derek Raghavan may publish in the future.

Co-authors

The 25 scholars most cited alongside Derek Raghavan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Derek Raghavan Line = papers co-authored together Derek Raghavan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 296 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Hit paper breakdown →
20042885
2
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Hit paper breakdown →
20012664
3
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
Hit paper breakdown →
20031867
4
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Hit paper breakdown →
20081753
5
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Hit paper breakdown →
1992756
6
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Hit paper breakdown →
2009486
7
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology
Hit paper breakdown →
2012464
8
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Hit paper breakdown →
1997394
9 2006367
10 1990332
11
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Hit paper breakdown →
2012327
12 1997279
13 2006218
14 2000174
15 2014165
16 2011165
17 2018163
18 1986163
19 2010154
20 2018135

About Derek Raghavan

Derek Raghavan is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology and Cancer Research, having authored 296 papers that have together received 19.2k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (83 papers), Prostate Cancer Treatment and Research (43 papers), Testicular diseases and treatments (38 papers), Urinary and Genital Oncology Studies (33 papers), Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (16 papers) and Cancer Research and Treatments (15 papers). The work is most often cited by research in Surgery (8.3k citations), Oncology (4.8k citations), Pulmonary and Respiratory Medicine (5.4k citations), Urology (993 citations) and Cancer Research (2.3k citations). Derek Raghavan has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Catherine M. Tangen, Maha Hussain, E. David Crawford, Eric J. Small, Donald G. Skinner, John P. Stein, Kenneth J. Pienta, Howard I. Scher, Johann S. de Bono and Michael F. Sarosdy. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Journal of Urology, Cancer Chemotherapy and Pharmacology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact